CCND1 and cancer: When the activation of NF-κB has been decreased, it can lead to a decrease in the expression of the genes that are related to the NF-κB pathway, such as cyclin D1, COX-2, Bcl, survivin, and MMP9.14 Finally, all the changes in the gene expression disrupt the function of specific transporters such as transporters P-glycoprotein (PGP), multidrug resistance-associated protein (MRP)-3, and ATP-binding cassette (ABC).75 These specific transporters can transport the anti-cancer drug to the extra-cellular fluid (ECF) and prevent the accumulation of the drug inside the cancer cells.